Ozempic, Wegovy ingredient may lower risk of Alzheimer’s, study finds

Ever since their rise in popularity as weight loss drugs , there's been a slew of reports on the potential adverse health affects of Ozempic and Wegovy .

However, a more recent study indicates that they may house an unforeseen benefit .

Specifically, the study — as published in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association" — has linked the active ingredient in both of these drugs, semaglutide, to lowering an individual's risk of Alzheimer's disease.

This analysis was conducted by researchers at Case Western Reserve School of Medicine in Cleveland, Ohio, over a three-year period. During this time they compared patients prescribed semaglutide to those prescribed one of seven other anti-diabetic drugs, and found that those taking the former saw their risk for Alzheimer's go down by 40 to 70 percent.

The study adds that "Similar reductions were seen across obesity status, gender, and age groups," although "further clinical trials to assess semaglutide's potential in delaying or preventing AD [Alzheimer's disease]."

"Semaglutide has been found to have anti-inflammatory and neuroprotective properties, which are crucial because inflammation and insulin resistance are both heavily involved in the progression of Alzheimer's disease," explained Dr. Ramit Singh Sambyal, a general physician associated with ClinicSpot, via Healthline .

Added he: "Brain insulin resistance is an emerging factor in Alzheimer's researcher, sometimes leading to the condition being dubbed 'type 3 diabetes' due to the metabolic dysfunctions observed in the brains of Alzheimer's patients."

As the study previously noted, further research in semglutide's potential role in alleviating or mitigating Alzheimer's disease remains pending.